다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Autoimmunity reviews, v.19 no.5, 2020년, pp.102523 -
Favalli, Ennio Giulio (Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute) , Ingegnoli, Francesca (Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute) , De Lucia, Orazio (Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute) , Cincinelli, Gilberto (Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università) , Cimaz, Rolando (degli Studi di Milano) , Caporali, Roberto (Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università)
AI-Helper
Abstract The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even...
1 Zhou P. Yang X.-L. Wang X.-G. Hu B. Zhang L. Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin Nature 579 2020 270 273 10.1038/s41586-020-2012-7 32015507
2 Tang X. Wu C. Li X. Song Y. Yao X. Wu X. On the origin and continuing evolution of SARS-CoV-2 Natl Sci Rev 2020 10.1093/nsr/nwaa036
3 Wu Z. McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Jama 323 2020 10.1001/jama.2020.2648
4 Zhang J.-J. Dong X. Cao Y.-Y. Yuan Y.-D. Yang Y.-B. Yan Y.-Q. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China Allergy 2020 10.1111/all.14238
5 Guan W.-J. Ni Z.-Y. Hu Y. Liang W.-H. Ou C.-Q. He J.-X. Clinical characteristics of coronavirus disease 2019 in China New Engl J Medicine 2020 10.1056/nejmoa2002032
6 Huang C. Wang Y. Li X. Ren L. Zhao J. Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet Lond Engl 395 2020 497 506 10.1016/s0140-6736(20)30183-5
7 Yang X. Yu Y. Xu J. Shu H. Xia J. Liu H. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Lancet Respir Med 2020 10.1016/s2213-2600(20)30079-5
8 https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd (Accessed 17 th March 2020)
9 Favalli E.G. Biggioggero M. Meroni P.L. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? Autoimmun Rev 13 2014 1102 1108 10.1016/j.autrev.2014.08.026 25172238
10 World Health Organization Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is Suspected: Interim Guidance 2020
11 Tisoncik J.R. Korth M.J. Simmons C.P. Farrar J. Martin T.R. Katze M.G. Into the eye of the cytokine storm Microbiol Mol Biology Rev Mmbr 76 2012 16 32 10.1128/mmbr.05015-11
12 Hoffmann M. Kleine-Weber H. Schroeder S. Krüger N. Herrler T. Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell 2020 10.1016/j.cell.2020.02.052
13 Zhao Y. Zhao Z. Wang Y. Zhou Y. Ma Y. Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov Biorxiv 2020 1 2020 26.919985 10.1101/2020.01.26.919985
14 Zou Z. Yan Y. Shu Y. Gao R. Sun Y. Li X. Angiotensin-converting enzyme 2 protects from lethal avian influenza a H5N1 infections Nat Commun 5 2014 3594 10.1038/ncomms4594 24800825
15 Fang L. Karakiulakis G. Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020 10.1016/s2213-2600(20)30116-8
16 G DS, Cardiology ES o. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers n.d.
17 Li X. Geng M. Peng Y. Meng L. Lu S. Molecular immune pathogenesis and diagnosis of COVID-19 J Pharm Analysis 2020 10.1016/j.jpha.2020.03.001
18 Yildiz H. Neste E.V.D. Defour J.P. Danse E. Yombi J.C. Adult haemophagocytic lymphohistiocytosis: a review Qjm Mon J Assoc Physicians 2020 10.1093/qjmed/hcaa011
19 Ramos-Casals M. Brito-Zerón P. López-Guillermo A. Khamashta M.A. Bosch X. Adult haemophagocytic syndrome Lancet 383 2013 1503 1516 10.1016/s0140-6736(13)61048-x 24290661
20 Seguin A. Galicier L. Boutboul D. Lemiale V. Azoulay E. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis Chest 149 2016 1294 1301 10.1016/j.chest.2015.11.004 26836913
21 Wan S. Yi Q. Fan S. Lv J. Zhang X. Guo L. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) Medrxiv 2020 10.1101/2020.02.10.20021832
22 Mehta P. McAuley D.F. Brown M. Sanchez E. Tattersall R.S. Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 2020 10.1016/S0140-6736(20)30628-0
23 Mathew A.J. Ravindran V. Infections and arthritis Best Pract Res Clin Rheumatol 28 2014 935 959 10.1016/j.berh.2015.04.009 26096095
24 Bogdanos D.P. Smyk D.S. Invernizzi P. Rigopoulou E.I. Blank M. Pouria S. Infectome: a platform to trace infectious triggers of autoimmunity Autoimmun Rev 12 2012 726 740 10.1016/j.autrev.2012.12.005 23266520
25 Arleevskaya M.I. Shafigullina A.Z. Filina Y.V. Lemerle J. Renaudineau Y. Associations between viral infection history symptoms, granulocyte reactive oxygen species activity, and active rheumatoid arthritis disease in untreated women at onset: results from a longitudinal cohort study of Tatarstan women Front Immunol 8 2017 1725 10.3389/fimmu.2017.01725 29259607
26 Joo Y.B. Lim Y.-H. Kim K.-J. Park K.-S. Park Y.-J. Respiratory viral infections and the risk of rheumatoid arthritis Arthritis Res Ther 21 2019 199 10.1186/s13075-019-1977-9 31470887
27 Listing J. Gerhold K. Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment Rheumatology (Oxford) 52 2012 53 61 10.1093/rheumatology/kes305 23192911
28 Galloway J.B. Hyrich K.L. Mercer L.K. Dixon W.G. Fu B. Ustianowski A.P. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology biologics register with special emphasis on risks in the elderly Rheumatology (Oxford) 50 2010 124 131 10.1093/rheumatology/keq242 20675706
29 Widdifield J. Bernatsky S. Paterson J.M. Gunraj N. Thorne J.C. Pope J. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis Arthritis Care Res 65 2013 353 361 10.1002/acr.21812
30 Doran M.F. Crowson C.S. Pond G.R. O’Fallon W.M. Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Arthritis Rheum 46 2002 2287 2293 10.1002/art.10524 12355475
31 Franklin J. Lunt M. Bunn D. Symmons D.P.M. Silman A.J. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis Ann Rheum Dis 66 2007 308 312 10.1136/ard.2006.057265 16984941
32 Au K. Reed G. Curtis J.R. Kremer J.M. Greenberg J.D. Strand V. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis Ann Rheum Dis 70 2011 785 791 10.1136/ard.2010.128637 21288960
33 Accortt N.A. Lesperance T. Liu M. Rebello S. Trivedi M. Li Y. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis Arthritis Care Res 70 2018 679 684 10.1002/acr.23426
34 Dougados M. Soubrier M. Antunez A. Balint P. Balsa A. Buch M.H. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) Ann Rheum Dis 73 2013 62 68 10.1136/annrheumdis-2013-204223 24095940
35 Ranganath V.K. Maranian P. Elashoff D.A. Woodworth T. Khanna D. Hahn T. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis Rheumatology 52 2013 1809 1817 10.1093/rheumatology/ket224 23813577
36 Smolen J.S. Landewé R.B.M. Bijlsma J.W.J. Burmester G.R. Dougados M. Kerschbaumer A. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis 2020 10.1136/annrheumdis-2019-216655
37 Strehl C. Ehlers L. Gaber T. Buttgereit F. Glucocorticoids-all-rounders tackling the versatile players of the immune system Front Immunol 10 2019 1744 10.3389/fimmu.2019.01744 31396235
38 Michaud K. Wolfe F. Comorbidities in rheumatoid arthritis Best Pract Res Clin Rheumatol 21 2007 885 906 10.1016/j.berh.2007.06.002 17870034
39 Boers M. Verhoeven A.C. Markusse H.M. van de Laar M.A. Westhovens R. van Denderen J.C. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis Lancet 350 1997 309 318 10.1016/s0140-6736(97)01300-7 9251634
40 van Everdingen A.A. Jacobs J.W.G. van Reesema D.R.S. Bijlsma J.W.J. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind Placebo-Controlled Clinical Trial Ann Intern Med 136 2002 1 10.7326/0003-4819-136-1-200201010-00006
41 Bakker M.F. Jacobs J.W.G. Welsing P.M.J. Verstappen S.M.M. Tekstra J. Ton E. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis Ann Intern Med 156 2012 329 10.7326/0003-4819-156-5-201203060-00004 22393128
42 Dixon W.G. Suissa S. Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses Arthritis Res Ther 13 2011 R139 10.1186/ar3453 21884589
43 Tang N.L.-S. Chan P.K.-S. Wong C.-K. To K-F Wu A.K.-L. Sung Y.-M. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome Clin Chem 51 2005 2333 2340 10.1373/clinchem.2005.054460 16195357
44 Arabi Y.M. Mandourah Y. Al-Hameed F. Sindi A.A. Almekhlafi G.A. Hussein M.A. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome Am J Resp Crit Care 197 2018 757 767 10.1164/rccm.201706-1172oc
45 Stockman L.J. Bellamy R. Garner P. SARS: systematic review of treatment effects PLoS Med 3 2006 e343 10.1371/journal.pmed.0030343
46 Memish Z.A. Perlman S. Kerkhove M.D.V. Zumla A. Middle East respiratory syndrome Lancet Lond Engl 2020 10.1016/s0140-6736(19)33221-0
47 Ni Y.-N. Chen G. Sun J. Liang B.-M. Liang Z.-A. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis Crit Care 23 2019 99 10.1186/s13054-019-2395-8 30917856
48 Lewis S.R. Pritchard M.W. Thomas C.M. Smith A.F. Pharmacological agents for adults with acute respiratory distress syndrome Cochrane Database Syst Rev 7 2019 CD004477 10.1002/14651858.cd004477.pub3
49 Russell C.D. Millar J.E. Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Lancet Lond Engl 395 2020 473 475 10.1016/s0140-6736(20)30317-2
50 Qiao W. Wang C. Chen B. Zhang F. Liu Y. Lu Q. Ibuprofen attenuates cardiac fibrosis in Streptozotocin-induced diabetic rats Cardiology 131 2015 97 106 10.1159/000375362 25896805
51 Lacaille D. Guh D.P. Abrahamowicz M. Anis A.H. Esdaile J.M. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis Arthritis Rheum 59 2008 1074 1081 10.1002/art.23913 18668604
52 Smitten A.L. Choi H.K. Hochberg M.C. Suissa S. Simon T.A. Testa M.A. The risk of hospitalized infection in patients with rheumatoid arthritis J Rheumatol 35 2008 387 393 18260176
53 Ibrahim A. Ahmed M. Conway R. Carey J.J. Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis J Clin Med 8 2018 15 10.3390/jcm8010015
54 Tudesq J.-J. Cartron G. Rivière S. Morquin D. Iordache L. Mahr A. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders Autoimmun Rev 17 2018 115 124 10.1016/j.autrev.2017.11.015 29180125
55 Ramiro S. Sepriano A. Chatzidionysiou K. Nam J.L. Smolen J.S. van der Heijde D. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis Ann Rheum Dis 76 2017 1101 1136 10.1136/annrheumdis-2016-210708 28298374
56 Favalli E.G. Desiati F. Atzeni F. Sarzi-Puttini P. Caporali R. Pallavicini F.B. Serious infections during anti-TNFα treatment in rheumatoid arthritis patients Autoimmun Rev 8 2009 266 273 10.1016/j.autrev.2008.11.002 19022409
57 Atzeni F. Sarzi-Puttini P. Botsios C. Carletto A. Cipriani P. Favalli E.G. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry Autoimmun Rev 12 2012 225 229 10.1016/j.autrev.2012.06.008 22796281
58 Rutherford A.I. Subesinghe S. Hyrich K.L. Galloway J.B. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Ann Rheum Dis 77 2018 905 910 10.1136/annrheumdis-2017-212825 29592917
59 Singh J.A. Cameron C. Noorbaloochi S. Cullis T. Tucker M. Christensen R. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis Lancet 386 2015 258 265 10.1016/s0140-6736(14)61704-9 25975452
60 Singh J.A. Wells G.A. Christensen R. Ghogomu E.T. Maxwell L.J. MacDonald J.K. Adverse effects of biologics: a network meta-analysis and Cochrane overview Cochrane Db Syst Rev 2011 CD008794 10.1002/14651858.cd008794.pub2
61 Atzeni F. Sarzi-Puttini P. Mutti A. Bugatti S. Cavagna L. Caporali R. Long-term safety of abatacept in patients with rheumatoid arthritis Autoimmun Rev 12 2013 1115 1117 10.1016/j.autrev.2013.06.011 23800448
62 Bello S.L. Serafino L. Bonali C. Terlizzi N. Fanizza C. Anecchino C. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents Reumatismo 64 2012 299 306 10.4081/reumatismo.2012.299 23256105
63 Shale M. Czub M. Kaplan G.G. Panaccione R. Ghosh S. Anti-tumor necrosis factor therapy and influenza: keeping it in perspective Ther Adv Gastroenter 3 2010 173 177 10.1177/1756283x10366368
64 Sepriano A. Kerschbaumer A. Smolen J.S. van der Heijde D. Dougados M. van Vollenhoven R. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis Ann Rheum Dis 2020 10.1136/annrheumdis-2019-216653
65 Favalli E.G. Matucci-Cerinic M. Szekanecz Z. The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis Autoimmun Rev 19 2019 102421 10.1016/j.autrev.2019.102421 31733368
66 Favalli E.G. Tofacitinib’s infectious profile: concerns for clinical practice Lancet Rheumatol 2 2020 e65 e67 10.1016/S2665-9913(20)30001-1
67 Winthrop K.L. Yamanaka H. Valdez H. Mortensen E. Chew R. Krishnaswami S. Herpes zoster and Tofacitinib therapy in patients with rheumatoid arthritis Arthritis Rheum 66 2014 2675 2684 10.1002/art.38745
68 Smolen J.S. Genovese M.C. Takeuchi T. Hyslop D.L. Macias W.L. Rooney T. Safety profile of Baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment J Rheumatol 46 2018 7 18 10.3899/jrheum.171361 30219772
69 Curtis J.R. Xie F. Yun H. Bernatsky S. Winthrop K.L. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis Ann Rheum Dis 75 2016 1843 1847 10.1136/annrheumdis-2016-209131 27113415
70 Pawar A. Desai R.J. Gautam N. Kim S.C. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study Lancet Rheumatol 2 2020 e84 e98 10.1016/s2665-9913(19)30137-7
71 Caporali R. Zavaglia D. Real-world experience with tofacitinib for treatment of rheumatoid arthritis Clin Exp Rheumatol 37 3 2019 485 495 30183607
72 Biggioggero M. Becciolini A. Crotti C. Agape E. Favalli E.G. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis Drugs Context 8 2019 212595 10.7573/dic.212595 31692920
73 Jamilloux Y. Jammal T.E. Vuitton L. Gerfaud-Valentin M. Kerever S. Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases Autoimmun Rev 18 2019 102390 10.1016/j.autrev.2019.102390 31520803
74 Winthrop K.L. The emerging safety profile of JAK inhibitors in rheumatic disease Nat Rev Rheumatol 13 2017 234 243 10.1038/nrrheum.2017.23 28250461
75 Liu C. Zhou Q. Li Y. Garner L.V. Watkins S.P. Carter L.J. Research and Development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases Acs Central Sci 2020 10.1021/acscentsci.0c00272
76 Zumla A. Chan J.F.W. Azhar E.I. Hui D.S.C. Yuen K.-Y. Coronaviruses - drug discovery and therapeutic options Nat Rev Drug Discov 15 2016 327 347 10.1038/nrd.2015.37 26868298
77 Lim J. Jeon S. Shin H.Y. Kim M.J. Seong Y.M. Lee W.J. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR J Korean Med Sci 35 2020 e79 10.3346/jkms.2020.35.e79
78 Mulangu S. Dodd L.E. Davey R.T. Mbaya O.T. Proschan M. Mukadi D. A randomized, controlled trial of Ebola virus disease therapeutics New Engl J Medicine 381 2019 2293 2303 10.1056/nejmoa1910993
79 Sheahan T.P. Sims A.C. Graham R.L. Menachery V.D. Gralinski L.E. Case J.B. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Sci Transl Med 9 2017 eaal3653 10.1126/scitranslmed.aal3653
80 Wang M. Cao R. Zhang L. Yang X. Liu J. Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res 30 2020 269 271 10.1038/s41422-020-0282-0 32020029
81 Widjaja I. Wang C. van Haperen R. Gutiérrez-Álvarez J. van Dieren B. Okba N.M.A. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein Emerg Microbes Infec 8 2019 516 530 10.1080/22221751.2019.1597644 30938227
82 Wang C. Li W. Drabek D. Okba N.M.A. van Haperen R. Osterhaus A.D.M.E. A human monoclonal 1 antibody blocking SARS-CoV-2 infection Biorxiv 2020 10.1101/2020.03.11.987958
83 Schrezenmeier E. Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology Nat Rev Rheumatol 16 2020 155 166 10.1038/s41584-020-0372-x 32034323
84 Inglot A.D. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs J Gen Virol 4 1969 203 214 10.1099/0022-1317-4-2-203 4306296
85 Keyaerts E. Vijgen L. Maes P. Neyts J. Ranst M.V. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine Biochem Bioph Res Co 323 2004 264 268 10.1016/j.bbrc.2004.08.085
86 Paton N.I. Lee L. Xu Y. Ooi E.E. Cheung Y.B. Archuleta S. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial Lancet Infect Dis 11 2011 677 683 10.1016/s1473-3099(11)70065-2 21550310
87 Roques P. Thiberville S.-D. Dupuis-Maguiraga L. Lum F.-M. Labadie K. Martinon F. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection Viruses 10 2018 268 10.3390/v10050268
88 Vincent M.J. Bergeron E. Benjannet S. Erickson B.R. Rollin P.E. Ksiazek T.G. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Virol J 2 2005 69 10.1186/1743-422x-2-69 16115318
89 Devaux C.A. Rolain J.-M. Colson P. Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Ag 105938 2020 10.1016/j.ijantimicag.2020.105938
90 Savarino A. Trani L.D. Donatelli I. Cauda R. Cassone A. New insights into the antiviral effects of chloroquine Lancet Infect Dis 6 2006 67 69 10.1016/s1473-3099(06)70361-9 16439323
91 Chinese Clinical Trial Registry. 2020.
92 Gao J. Tian Z. Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Biosci Trends 2020 10.5582/bst.2020.01047
93 Yao X. Ye F. Zhang M. Cui C. Huang B. Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis 2020 10.1093/cid/ciaa237
94 Diao B. Wang C. Tan Y. Chen X. Liu Y. Ning L. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Medrxiv 2020 10.1101/2020.02.18.20024364
95 Shakoory B. Carcillo J.A. Chatham W.W. Amdur R.L. Zhao H. Dinarello C.A. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome Crit Care Med 44 2016 275 281 10.1097/ccm.0000000000001402 26584195
96 Xu X. Han M. Li T. Sun W. Wang D. Fu B. Effective treatment os severe COVID-19 patients with tocilizumab ChinaXiv:20200300026 2020
97 http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19 (Accessed 17 th March 2020)
98 Wang W. He J. Puyi Lie Liyan Huang Wu S. Yongping Lin The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis Medrxiv 2020 10.1101/2020.02.26.20026989
99 Haga S. Yamamoto N. Nakai-Murakami C. Osawa Y. Tokunaga K. Sata T. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry Proc Natl Acad Sci U S A 105 2008 7809 7814 10.1073/pnas.0711241105 18490652
100 Wang W. Ye L. Ye L. Li B. Gao B. Zeng Y. Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway Virus Res 128 2007 1 8 10.1016/j.virusres.2007.02.007 17532082
101 Sorrell F.J. Szklarz M. Azeez K.R.A. Elkins J.M. Knapp S. Family-wide structural analysis of human numb-associated protein kinases Struct Lond Engl 1993 24 2016 401 411 10.1016/j.str.2015.12.015
102 Lu R. Zhao X. Li J. Niu P. Yang B. Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Lancet Lond Engl 395 2020 565 574 10.1016/s0140-6736(20)30251-8
103 Bekerman E. Neveu G. Shulla A. Brannan J. Pu S.-Y. Wang S. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects J Clin Invest 127 2017 1338 1352 10.1172/jci89857 28240606
104 Stebbing J. Phelan A. Griffin I. Tucker C. Oechsle O. Smith D. COVID-19: combining antiviral and anti-inflammatory treatments Lancet Infect Dis 2020 10.1016/s1473-3099(20)30132-8
105 Pu S.-Y. Xiao F. Schor S. Bekerman E. Zanini F. Barouch-Bentov R. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment Antiviral Res 155 2018 67 75 10.1016/j.antiviral.2018.05.001 29753658
106 Richardson P. Griffin I. Tucker C. Smith D. Oechsle O. Phelan A. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Lancet Lond Engl 395 2020 e30 e31 10.1016/s0140-6736(20)30304-4
107 Ferguson F.M. Gray N.S. Kinase inhibitors: the road ahead Nat Rev Drug Discov 17 2018 353 377 10.1038/nrd.2018.21 29545548
108 Sanchez G.A.M. Reinhardt A. Ramsey S. Wittkowski H. Hashkes P.J. Berkun Y. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies J Clin Invest 128 2018 3041 3052 10.1172/jci98814 29649002
109 Virtanen A.T. Haikarainen T. Raivola J. Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases Biodrugs Clin Immunother Biopharm Gene Ther 33 2019 15 32 10.1007/s40259-019-00333-w
110 Borden E.C. Sen G.C. Uze G. Silverman R.H. Ransohoff R.M. Foster G.R. Interferons at age 50: past, current and future impact on biomedicine Nat Rev Drug Discov 6 2007 975 990 10.1038/nrd2422 18049472
111 Schoggins J.W. Wilson S.J. Panis M. Murphy M.Y. Jones C.T. Bieniasz P. Corrigendum: a diverse range of gene products are effectors of the type I interferon antiviral response Nature 525 2015 144 10.1038/nature14554
112 Fleming S. Viral inhibition of the IFN-induced JAK/STAT Signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists Nato Adv Sci Inst Se 4 2016 23 10.3390/vaccines4030023
113 Ayllon J. García-Sastre A. Current topics in microbiology and immunology Curr Top Microbiol 386 2014 73 107 10.1007/82_2014_400
114 Jia D. Rahbar R. Chan R.W.Y. Lee S.M.Y. Chan M.C.W. Wang B.X. Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling PLoS One 5 2010 e13927 10.1371/journal.pone.0013927
115 Conigliaro P. Triggianese P. Martino E.D. Fonti G.L. Chimenti M.S. Sunzini F. Challenges in the treatment of rheumatoid arthritis Autoimmun Rev 18 2019 706 713 10.1016/j.autrev.2019.05.007 31059844
116 Favalli E.G. Raimondo M.G. Becciolini A. Crotti C. Biggioggero M. Caporali R. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives Autoimmun Rev 16 2017 1185 1195 10.1016/j.autrev.2017.10.002 29037899
117 Edwards C.J. Galeazzi M. Bellinvia S. Ringer A. Dimitroulas T. Kitas G. Can we wean patients with inflammatory arthritis from biological therapies? Autoimmun Rev 18 2019 102399 10.1016/j.autrev.2019.102399 31639516
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.